MedTrace Logo

Study of Oral Palifosfamide Tris in Solid Tumors

NCT00607711 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-05-05

No results posted yet for this study

Summary

The study of maximum tolerated dose and safety of oral palifosfamide tris capsules in advanced, refractory, solid tumors

Conditions

Interventions

DRUG

oral palifosfamide tris

Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.

Sponsors & Collaborators

  • Alaunos Therapeutics

    lead INDUSTRY

Principal Investigators

  • Sachin Shah, MD · ZIOPHARM Oncology, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-11-30
Completion
2009-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607711 on ClinicalTrials.gov